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ABSTRACT
Objectives To determine how gene expression profiles 
in osteoarthritis joint tissues relate to patient phenotypes 
and whether molecular subtypes can be reproducibly 
captured by a molecular classification algorithm.
Methods We analysed RNA sequencing data from 
cartilage and synovium in 113 osteoarthritis patients, 
applying unsupervised clustering and Multi- Omics Factor 
Analysis to characterise transcriptional profiles. We 
tested the association of the molecularly defined patient 
subgroups with clinical characteristics from electronic 
health records.
Results We detected two patient subgroups in low- 
grade cartilage (showing no/minimal degeneration, 
cartilage normal/softening only), with differences 
associated with inflammation, extracellular matrix- 
related and cell adhesion pathways. The high- 
inflammation subgroup was associated with female 
sex (OR 4.12, p=0.0024) and prescription of proton 
pump inhibitors (OR 4.21, p=0.0040). We identified 
two independent patient subgroupings in osteoarthritis 
synovium: one related to inflammation and the other to 
extracellular matrix and cell adhesion processes. A seven- 
gene classifier including MMP13, APOD, MMP2, MMP1, 
CYTL1, IL6 and C15orf48 recapitulated the main axis of 
molecular heterogeneity in low- grade knee osteoarthritis 
cartilage (correlation ρ=−0.88, p<10−10) and was 
reproducible in an independent patient cohort (ρ=−0.85, 
p<10−10).
Conclusions These data support the reproducible 
stratification of osteoarthritis patients by molecular 
subtype and the exploration of new avenues for tailored 
treatments.
INTRODUCTION
Our understanding of the molecular mechanisms 
that underlie the observed epidemiological and 
clinical heterogeneity in osteoarthritis (OA) is 
incomplete. The accessibility of primary disease 
tissues at the point of joint replacement surgery 
provides the opportunity to stratify patients based 
on tissue- specific molecular profiles. Such stratifi-
cation may help provide mechanistic insights into 
the molecular processes underlying the disease and 
subsequently develop novel tailored treatments. 
By examining expression profiles in cartilage, two 
previous studies in small cohorts have identified 
two subgroups of patients: microarray data from 
23 patients suggested subgroups with gene expres-
sion differences related to inflammatory response, 
leucocyte activation, regulation of cytokine produc-
tion and chemokine activity1; RNA sequencing data 
from 44 patients also suggested two subgroups, but 
with differences related to oxidative stress, innate- 
immune responses, Wnt signalling and chemokine 
signalling rather than classical inflammation.2
Several questions emerge from these studies: 
Do molecular profiles in different disease- relevant 
tissues define the same patient subgroups? Is the 
molecular subgrouping associated with any clin-
ical characteristics? Is the molecular subgrouping 
Key messages
What is already known about this subject?
 ► Osteoarthritis (OA) is a disease with both 
clinical and molecular heterogeneity.
 ► However, it remains unclear whether 
molecular subgroupings of patients vary 
between joint tissue types, how they relate 
to clinical characteristics and whether they 
can be reproducibly captured by a molecular 
classification algorithm.
What does this study add?
 ► We carried out the first in- depth 
characterisation of molecular heterogeneity 
using patient synovium and cartilage in the 
largest cohort to date.
 ► We detected two patient subgroups based on 
low- grade (largely intact) OA cartilage, which 
were associated with sex and proton pump 
inhibitor prescription. Patient subgroups in 
synovium were associated with inflammation 
and, separately, extracellular matrix and cell 
adhesion, and were independent of the low- 
grade OA cartilage subgroups.
 ► A seven- gene classifier reproducibly 
recapitulated both the discrete assignment of 
knee low- grade OA cartilage subgroups and the 
main continuous spectrum of variation within 
the tissue.
How might this impact on clinical practice or 
future developments?
 ► These data demonstrate that molecular 
tissue profile in OA is associated with patient 
clinical characteristics, that this profile can be 
characterised using a limited panel of genes, 
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truly categorical or better reflected by a continuous spectrum 
of variation? Can a molecular classification algorithm repro-
ducibly recapitulate both categorical subgrouping and the main 
continuous spectrum of variation? Here, we examine these ques-
tions through genome- wide transcriptional profiling of multiple 
primary patient tissues (low- grade OA cartilage, high- grade OA 
cartilage and synovium), integrating information from electronic 
health records, and substantially increasing the cohort size and 
hence power (doubling the size of the discovery sample and 
almost tripling the total number of patients with genome- wide 
data compared with past studies).
MATERIAL AND METHODS
Patients
We analysed tissue samples from 113 patients undergoing total 
joint replacement surgery (table 1). All patients gave informed 
written consent prior to participation (online supplemental 
methods). Matched low- grade and high- grade OA cartilage 
samples (ie, largely intact vs degraded tissue, respectively; see 
online supplemental methods) were collected from each patient 
and synovial lining samples from 90 knee OA patients (table 1). 
All cartilage samples were collected from weight- bearing areas 
of the joint, ensuring that any differences observed between 
low- grade and high- grade OA cartilage reflected disease severity 
rather than differential mechanical loading. Cartilage scoring, 
isolation of chondrocytes and synoviocytes, and RNA extraction 
are described in online supplemental methods.
For knee OA patients, we obtained clinical characteristics and 
prescribed drugs from the electronic patient records (online 
supplemental methods).
RNA sequencing
Multiplexed libraries were sequenced on the Illumina HiSeq 
2000 or HiSeq 4000 (75bp paired- end reads). After quality 
control, we applied salmon 0.8.2,3 and tximport4 to obtain 
gene- level scaled transcripts per million estimates (online supple-
mental methods).
Molecular subgroups
We applied limma- voom5 to remove heteroscedasticity from gene 
expression data, permuted Surrogate Variable Analysis (pSVA)6 
to remove technical variation and explicitly regressed out effects 
of known sample collection and sequencing batches. We then 
applied ConsensusClusterPlus7 to identify discrete molecularly 
defined subgroups (‘clusters’) of patients, with a sensitivity anal-
ysis to verify that clustering was similar when restricting to knee 
OA patients only (online supplemental text). We tested differen-
tial gene expression between clusters using limma,8 and applied 
SPIA9 and GOseq10 to identify associated biological processes 
(online supplemental methods).
Associations between molecular clusters and clinical 
characteristics
We tested for association between cluster assignment and clin-
ical characteristics using a generalised linear model and applied 
a Bonferroni multiple- testing correction for the effective number 
of tests (p<0.0047, online supplemental methods). As sensitivity 
analyses, we successively added the following covariates to the 
models: sex, age, OA joint, body mass index (online supple-
mental methods).
In-depth characterisation of molecular heterogeneity
To test for patient heterogeneity using a method that can detect 
both discrete clustering and a continuous spectrum of variation, 
we used Multi- Omics Factor Analysis (MOFA).11 We investi-
gated the correspondence between the discrete clusters and the 
continuous spectrum of variation identified by the MOFA and 
carried out extensive sensitivity analyses to verify robustness of 
the MOFA results (online supplemental methods).
Low-grade OA cartilage classifier
We used the 'Prediction analysis for microarrays for R' (PAMR)12 
package to construct a classifier which used a smaller subset of 
genes to recapitulate the main axis of molecular heterogeneity in 
knee low- grade OA cartilage (online supplemental methods). We 
validated the classifier using an independent publicly- available 
dataset from 60 knee OA patients2 (table 1, online supplemental 
methods).
RESULTS
After quality checks, we analysed transcriptomic profiles of 259 
tissue samples from 106 patients (table 1).
Do molecular profiles in different tissues define the same 
patient subgroups?
Using consensus clustering, we identified two robust patient clus-
ters in synovium, each of which further formed two subclusters 
(figure 1A). We also identified two robust patient clusters within 
low- grade, but not high- grade OA, cartilage (figure 1B, online 
supplemental figure 1). Cartilage clustering was independent of 
the synovium clusters (Fisher’s p>0.66), and not associated with 
patient cohort nor with sequencing batches (χ2 test, p>0.96).
Signalling Pathway Impact Analysis9 showed that the differ-
ences between the two synovium patient clusters relate to 
inflammation, while differences between the sub- clusters relate 
to the extracellular matrix and to cell adhesion (figure 1C,D, 
online supplemental figure 2, table 1 and text). The differences 
between low- grade OA cartilage clusters were also strongly asso-
ciated with inflammation, extracellular matrix- related and cell 
adhesion pathways (figure 1E, online supplemental table 1).
Table 1 Characteristics of patients in discovery and validation cohorts
Variable Discovery total Discovery cohort 1 Discovery cohort 2 Discovery cohort 3 Discovery cohort 4 Validation
No of patients (after QC) 113 (106) 12 (11) 20 (17) 11 (10) 70 (68) 60 (60)
Osteoarthritis joint Knee or hip Knee Knee Hip Knee Knee
Low- grade OA cartilage samples after QC 87 11 16 10 50 60
High- grade OA cartilage samples after QC 95 10 16 10 59 –
Synovium samples after QC 77 – 16 – 61 –
Females, n (%) after QC 63 (59) 2 (19) 12 (71) 8 (73) 41 (60) 27 (45)
Age, average years (range) after QC 69 (38–88) 69 (50–88) 70 (54–79) 61 (44–88) 70 (38–84) 72 (63–85)
OA, osteoarthritis; QC, quality control.
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Figure 1 Distinct molecularly defined patient clusters identified in low- grade OA cartilage and synovium tissue. (A) Two clusters of patients based 
on consensus clustering of synovium RNA data. Each cluster formed two subclusters, with one outlier sample. (B) Two clusters of patients based 
on consensus clustering of low- grade OA cartilage RNA data. (C) Gene expression differences between synovium clusters show several significant 
(false discovery rate <5%) associations related to inflammation and osteoclast differentiation using Signalling Pathway Impact Analysis (SPIA). Here 
and below, P: p values based on enrichment of genes; perturbation of the pathway based on gene log- fold differences; or combining enrichment 
and perturbation. The associations shown are robust across several gene- level differential expression cut- offs (online supplemental table 1). (D) 
Gene expression differences between the synovium subclusters within each cluster show similar pathway associations, including to ECM–receptor 
interaction and focal adhesion pathways. (E) Gene expression differences between low- grade OA cartilage clusters show significant associations 
with inflammation and osteoclast differentiation pathways. (F) An analysis of low- grade OA cartilage samples using MOFA identifies a continuous 
spectrum of variation between samples, which corresponds to the identified clusters. Samples with intermediate MOFA factor 1 scores have lower 
Silhouette scores, showing more uncertainty in cluster assignment. For synovium, see online supplemental figure 3. ECM, extracellular matrix; FDR, 
false discovery rate; MOFA, Multi- Omics Factor Analysis; OA, osteoarthritis.
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Is the molecular subgrouping associated with clinical 
characteristics?
We found that women were more likely to be members of the 
cartilage cluster characterised by higher inflammation (OR=4.12, 
p=0.0024; online supplemental table 2 and text). Patients in the 
high- inflammation cluster were also more likely to be prescribed 
proton pump inhibitors (PPIs; OR=4.21, p=0.0040; online 
supplemental text). We did not detect significant associations 
between synovium clustering and clinical characteristics (online 
supplemental table 2 and text).
Is the molecular clustering categorical or continuous?
MOFA11 identified continuous axes of variation within synovium 
and low- grade OA cartilage tissue that correspond strongly with 
cluster assignment (figure 1F, online supplemental figures 3 
and 4, online supplementary text). In low- grade OA cartilage, 
the first MOFA factor (ie, the main axis of variation) explained 
28% of variation in gene expression levels; the gene expression 
weights for this first factor and the log- fold- differences between 
clusters had very high correlation (Pearson correlation r=0.91, 
p<10−15; online supplemental figure 4). These findings were 
also recapitulated in synovium (r 0.83–0.96 for gene weights for 
the first two MOFA factors and the log- fold- differences between 
synovium clusters and subclusters; online supplemental figure 
4). This suggests that the variation within these tissues is better 
represented as a continuous spectrum.
We verified robustness of the MOFA results using extensive 
sensitivity analyses (including restricting analysis to knee OA 
patients only or explicitly regressing out age and sex effects; 
online supplemental text).
Can a classifier reproducibly recapitulate both categorical 
clustering and the main axis of variation?
We used a soft- thresholding centroid- based method, PAMR,12 to 
construct a tool that can recapitulate the clustering and main axis 
of heterogeneity in low- grade OA cartilage. As clinical and research 
applications would likely differ between OA joints, we restricted the 
analysis to patients with knee OA. The resulting tool predicts prob-
abilities of knee low- grade OA cartilage cluster assignment based on 
the expression levels of seven genes (figure 2A, online supplemental 
figure 5, Data availability): MMP1, MMP2 and MMP13, which are 
involved in cartilage degradation13; IL6, a proinflammatory cyto-
kine; CYTL1, a cytokine- like gene, loss of which has been found to 
augment cartilage destruction in surgical OA mouse models14; APOD, 
a component of high- density lipoprotein found to be strongly upreg-
ulated by retinoic acid,15 which is in turn regulated by ALDH1A2,16 
an OA risk locus17 18 and C15orf48, of currently unknown function. 
Notably, the probabilities for cluster assignment generated by the 
classifier captured the main continuous spectrum of variation in this 
tissue (Spearman’s correlation ρ=−0.88, p<10−10; figure 2B). We 
validated the seven- gene classifier in an independent gene expression 
dataset of low- grade OA cartilage samples from 60 knee OA patients 
undergoing joint replacement surgery.2 The posterior probabilities 
for cluster assignment had good correspondence to the main contin-
uous spectrum of variation in the validation samples, supporting the 
predictive potential of the seven- gene classifier (ρ=−0.85, p<10−10; 
figure 2C).
We also found that the seven- gene classifier had improved 
generalisability compared with a classifier developed in previous 
work2: the majority of genes in the previously developed clas-
sifier showed either discordant expression differences between 
the clusters in our larger dataset or high false discovery rates 
(>30%; online supplemental table 3 and text).
DISCUSSION
Our findings indicate that molecular heterogeneity in OA carti-
lage and synovium is associated with similar biological processes 
(including inflammation), but molecularly defined patient clus-
ters differ between tissues, potentially reflecting differences in 
tissue- specific dominant disease processes.
The clustering in low- grade OA cartilage agrees with two 
previous smaller studies.1 2
We also identified an association between the cartilage high- 
inflammation cluster and female sex, which is consistent with the 
Figure 2 Clustering and main axis of variation within knee low- grade OA cartilage can be recapitulated using a seven- gene classifier. (A) PAMR 
scores for each gene in the seven- gene knee OA classifier (the difference between the standardised centroids of the two clusters) and the differential 
expression of the genes between the two low- grade OA cartilage clusters. See online supplemental figure 5 for classifier performance. (B) The PAMR 
posterior probabilities for cluster assignment are highly correlated with MOFA factor 1 scores for knee low- grade OA cartilage samples, capturing 
the main continuous spectrum of variation between samples. Inset: Spearman correlation, p<10−10. (C) In an independent set of 60 low- grade OA 
cartilage samples from 60 knee OA patients, the posterior probabilities for cluster assignment from the seven- gene classifier are well correlated with 
the continuous spectrum of variation in these samples, as quantified by the first MOFA factor in an ab initio analysis. Inset: Spearman’s correlation, 
p<10−10. IL, interleukin; MOFA, Multi- Omics Factor Analysis; OA, osteoarthritis.
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disproportionate increase in the incidence of OA in women after 
the menopause. This association might be explained by the lower 
concentration of oestrogen and androgens (which have established 
anti- inflammatory effects) in postmenopausal women.19 20 We spec-
ulate that our observed association between the high- inflammation 
cluster and PPI use could be explained by over the counter use of 
non- steroidal anti- inflammatory drugs for which PPIs are commonly 
coprescribed. We did not see discrete subgrouping in high- grade OA 
cartilage, perhaps indicating that there is less clear variation in molec-
ular profiles in cartilage with advanced degeneration.
Our MOFA results further confirmed that the main axis of vari-
ation was related to inflammation in both synovium and cartilage. 
The seven- gene classifier generated using PAMR was able to place 
knee OA patients along the inflammatory endotype axis of variation 
and confirmed that such classification reflects continuous variation 
rather than categorical clustering, with validation in independent 
data. This finding has implications for the development of thera-
peutic strategies for OA, providing empirical evidence that responses 
might be expected to be heterogeneous along an axis of variation, 
rather than discrete. However, further study will be required to 
determine to what extent the inflammation axis is present in earlier 
disease stages, is stable across time or differs with disease activity, 
which cartilage scoring system is best suited to detect this axis, and 
whether the classifier can be applied to or modified for peripheral 
tissue (eg, saliva or blood). We anticipate that, looking ahead, this 
approach could underpin tailored therapy development and help 
improve patient care.
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Supplemental text 
Associations between clusters and biological pathways 
To help interpret gene expression differences between clusters detected in synovium, we 
carried out pathway enrichment analyses using SPIA. This is a within-tissue analysis, thus 
different from comparisons of e.g. osteoarthritis tissue to health tissue. If a pathway is 
generally dysregulated in osteoarthritis disease tissue, the within-tissue analysis is expected 
to show no association. By contrast, we found multiple associations between synovium 
clusters that related to inflammation, including Chemokine signalling and Leukocyte 
transendothelial migration (figure 1c, online supplemental table 1). By contrast, differences 
between the sub-clusters related to the extracellular matrix and to cell adhesion (figure 1d, 
online supplemental table 1). 
In an analogous comparison of differences between low-grade cartilage clusters, we also 
found associations with pathways related to inflammation, including Cytokine-cytokine 
receptor interaction and Chemokine signalling (figure 1e, online supplemental table 1). 
These results were supported by enrichment analyses based on Gene Ontology annotations  
(online supplemental table 1). 
These results also agree with previous studies that have found low-grade cartilage clusters 
with differences associated with inflammation.[1, 2] As a limitation to this comparison, we 
note that the previously published studies used gene annotation data prior to 2014 and 
2018, respectively, and these annotations would thus differ to those used in the current 
study. 
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Patient low-grade OA cartilage clusters identified in previous work 
Previous studies in smaller patient sets have identified discrete subgroups by using gene 
expression arrays or RNA sequencing in low-grade OA cartilage.[1, 2] Here, we substantially 
increase sample size and hence power, and are able to test for overlap between clusters 
identified from different tissues, test for associations with clinical characteristics, and 
evaluate whether the clustering is truly categorical or better represented by a continuous 
spectrum of variation. 
 
A previous study using array-based gene expression data across 23 patients identified two 
clusters in low-grade OA cartilage, with differences related to inflammation.[1] Of the 9 
genes validated using qRT-PCR, 6 were also present in our data (including all 5 genes with 
significant differences in the original validation sample), and all showed significant 
differences in a concordant direction between the two cartilage clusters (online 
supplemental table 3). However, this previous study did not develop a classifier that could 
be applied to other data.  
 
Another study used RNA sequencing data from low-grade OA cartilage of 44 knee 
osteoarthritis patients and applied a network-based approach to identify two patient 
groups, with differences related to inflammation, Wnt signalling, and calcium regulation.[2] 
This group assignment corresponded to the categorical cluster assignment from the 7-gene 
classifier constructed in this study for 70% of the samples (31 out of 44 samples with 
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available data). We further considered the certainty of the original group assignment as 
previously published[2]. Of the 18 samples with high silhouette scores (>0.7) signifying 
strong cluster assignment in the original analysis, 14 had a concordant dichotomous 
prediction by PAMR (78%).  
To distinguish between the two patient groups, this previous study also constructed a 
classifier based on the expression of 10 genes in 44 patients; 7 of these genes also showed 
qPCR differences between two groups in a second cohort of 16 patients. Of these 7 genes, 
all were present in our data, but the majority showed a discordant direction of effect or 
higher false-discovery rates (33.5-99.8% FDR) between the low-grade OA cartilage clusters 
detected in our larger discovery cohort (83 patients; online supplemental table 3). By 
contrast, all 7 genes used by the 7-gene classifier constructed in the current work showed 
concordant differences between the two groups from the previous study (MMP1, MMP2, 
MMP12 showed significant differences at 0.07% FDR; APOD, CYTL1, C15orf48 at 11-15% 
FDR; IL6 at 25.5% FDR), indicating improvement in transferability.  
 
We also note that previous studies have focused their validation efforts on detecting 
differences in expression of individual genes using qPRC. By contrast, we validated the full 7-
gene classifier in a completely independent gene expression dataset (patients samples 
collected in different hospitals, RNA sequenced and quantified in a different centre). 
Consequently, the strong correspondence of the posterior probabilities for cluster 
assignment with an ab initio MOFA analysis of the independent validation data (figure 2c) 
further speaks to the strong transferability of the 7-gene classifier from this work. 
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Continuous spectrum of variation within synovium and cartilage tissues 
corresponds to patient clusters 
Disease endpoints and discrete endotypes represent underlying processes that may be 
more sensitively captured by continuous axes of variation within the molecular data rather 
than categorical classifiers. Such an approach may help define disease trajectories earlier in 
the natural history of osteoarthritis. To evaluate this, we applied Multi-Omics Factor 
Analysis (MOFA),[3] an integrative method that can discover hidden factors that represent 
drivers of variability between samples or patients (latent factors) that is akin to a cross-data 
principal component analysis.  
When analysing all tissues together, we identified latent factors (axes of variation) that were 
each predominantly related to one tissue only. MOFA detected 8 factors that together 
captured 45-63% of the variance in the RNA data in each tissue. The first factor captured 
27% of the variance in the synovium and was strongly associated with pathways related to 
the complement cascade, ECM organisation, diseases of glycosylation, binding and uptake 
of ligands, ECM proteoglycans, membrane trafficking, and others (see Data availability). The 
second factor captured 24% of the variance in low-grade OA cartilage and was strongly 
associated with various immune system processes (chemokines binding chemokine 
receptors, interleukin signalling, cytokine signalling, and others) and the ECM (ECM 
organisation, collagen degradation, assembly of collagen fibrils and other multimeric 
structures, collagen formation, and others; see Data Availability). The association of the first 
two factors with immune system processes and the extracellular matrix is in keeping with 
the biological pathways identified to play an important role based on the clustering analysis.  
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2020-219760–5.:10 2021;Ann Rheum Dis, et al. Steinberg J
For the comparison of consensus clustering and MOFA, we sought to capture more fine-
grained within-tissue results in MOFA and thus carried out MOFA separately for each tissue. 
We found that the continuous axes of variation within low-grade OA cartilage and synovium 
correspond strongly with cluster assignment (figure 1f, online supplemental figure 3). This is 
consistent with variation within tissues being better captured as a continuous spectrum 
rather than as discrete clusters. 
In low-grade OA cartilage, the first MOFA factor (i.e. the main axis of variation) explained 
28% of variation in gene expression levels and demonstrated strong correspondence with 
the cluster assignment. In agreement with this, we found that the gene expression weights 
for this first factor and the log-fold-differences between clusters had very high correlation 
(Pearson r=0.91, p<10-15; online supplemental figure 4a).  
 
We would therefore expect that in each cartilage cluster, gene expression differences 
between samples with low versus high factor scores would mirror differences between the 
clusters. To test this, we compared the gene expression differences between subsets of the 
discrete cartilage clusters at a MOFA low-grade OA Factor 1 threshold of 0, which 
corresponded most closely to the cluster assignment, with consistent assignment for 84% of 
patients in cartilage-Cluster1 (38 of 45 with score >0) and 83% of patients in cartilage-
Cluster2 (35 out of 42 with score <0). We analysed gene expression differences between the 
38 and 7 samples in cartilage-Cluster1 with MOFA low-grade OA Factor 1 values above and 
below 0, respectively. Analogously, we analysed gene expression differences between the 7 
and 35 samples in cartilage-Cluster2 with MOFA low-grade OA Factor 1 values above and 
below 0, respectively. Indeed, in both comparisons, we found that 85-92% of genes with 
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significant expression differences also showed significant expression differences between 
the clusters, and all but two genes in the expected direction (online supplemental figure 4b).  
 
 These findings were also recapitulated in synovium, for which MOFA Factors 1 and 2 also 
showed good correspondence to the division of samples into clusters (online supplemental 
figure 4c). Moreover, we found high correlation between the MOFA synovium Factor 2 RNA 
weights and log-fold-differences between synovium clusters (Pearson correlation r=0.83, 
p<10-15; online supplemental figure 4c), as well as between MOFA synovium Factor 1 RNA 
weights and log-fold-differences between synovium sub-clusters (Pearson correlation 
r>0.919, p<10-15; online supplemental figure 4c). 
 
 
Associations between molecular clusters and clinical characteristics 
To verify the robustness of the associations between clinical characteristics and low-grade 
OA cartilage clusters, we carried out sensitivity analyses explicitly adjusting for i) sex; ii) sex 
and age; iii) sex, age, and osteoarthritis joint; iv) sex, age, and BMI (based on knee 
osteoarthritis patients only, as we did not have BMI information for hip osteoarthritis 
patients). In addition, we also tested associations adjusting for sex and age, based on data 
from knee osteoarthritis patients only. In all these analyses, we observed qualitatively and 
quantitatively similar effects (online supplemental table 2). In fact, the associations with sex 
and prescription of proton pump inhibitors became stronger and more significant when sex 
and age were explicitly adjusted for (female sex: OR=5.14 and p=0.0010 versus unadjusted 
OR=4.12 and p=0.0024; prescription of proton pump inhibitors: OR=5.16 and p=0.0034 
versus unadjusted OR=4.21 and p=0.0040). The association with sex also remained 
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significant in the analysis adjusting for sex, age, and osteoarthritis joint (OR=5.12, 
p=0.00123), and in the analysis adjusting for sex and age while using data from knee 
osteoarthritis patients only (OR=4.61, p=0.00292). In both of these analyses, the association 
with proton pump inhibitors was the same as in the sensitivity analysis adjusting for age and 
sex, as the medication analyses were already restricted to knee osteoarthritis patients only. 
When adjusting for age, sex, and BMI, the effect estimates for both sex and proton pump 
inhibitors were only slightly lower and retained nominal significance, although they were no 
longer significant after Bonferroni-correction (OR=3.94, p=0.0087 and OR=4.88, p=0.00645); 
we note that reduced significance could be due to a smaller number of patients and 
inclusion of an additional covariate in this analysis. 
 
Several further clinical characteristics were associated with cluster assignment at nominal 
significance in the main analysis: patients in the high-inflammation cluster were more likely 
to be prescribed a higher number of drugs (unadjusted OR=1.21 per additional drug, 
p=0.023; adjusted for age and sex: OR=1.17 per additional drug, p=0.086) and to be older 
(unadjusted OR=1.06 per year, p=0.036; adjusted for sex: OR=1.06 per year, p=0.013). 
These findings support a mechanistic explanation of the established association between 
osteoarthritis, age, sex, multimorbidity and polypharmacy,[4, 5] although the direction of 
causation remains unclear.  
 
For the association between cartilage clustering and prescription of proton pump inhibitors, 
we note that these drugs are often co-administered with non-steroidal anti-inflammatory 
drugs (NSAIDs) to reduce risk of gastrointestinal adverse effects due to NSAID use.[6] 
NSAIDs are very commonly used to relieve osteoarthritis pain, but can be bought without a 
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prescription in the United Kingdom (at low dose, which is often recommended to reduce the 
risk of adverse events).[7] Thus, it also possible that the association between cartilage 
clusters and proton pump inhibitors is due to confounding by NSAID use. As data on non-
prescription medication use were not available in this study, we could not investigate this 
hypothesis further.  
 
While we did not detect any significant associations between synovium clustering and 
clinical characteristics, we note that the smaller number of patients with synovium tissue 
reduced power to detect an association.  
 
 
Clustering and MOFA sensitivity analyses based on samples from knee OA 
patients only 
We carried out extensive sensitivity analyses to verify that the clustering and MOFA results 
were robust when restricted to knee OA patients only, and were not driven by cohort 
effects. 
Clustering analyses 
First, we checked that clustering was not associated with patient cohort (chi-square test, 
p>0.99 in synovium and low-grade OA cartilage), nor with batches samples were sent and 
sequenced (chi-square test, p>0.96 in synovium and low-grade OA cartilage). 
Second, we re-ran clustering analyses for low-grade and high-grade OA cartilage using 
samples from knee OA patients only.  
For high-grade cartilage, we again did not see robust clustering as in the main analysis 
(cluster consensus scores <0.8, online supplemental figure 6a). 
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For low-grade cartilage, the analysis based on knee OA patients identified 2 clusters very 
similar to the main analysis: 91% (70/77) of samples were assigned to the same cluster (33 
to Cluster 1, 37 to Cluster 2), while 7 samples were assigned to Cluster 2 in the sensitivity 
analysis, but Cluster 1 in the main analysis. Notably, all 7 patients had intermediate MOFA 
low-grade OA Factor 1 scores (online supplemental figure 6b), suggesting that the re-
assignment may be due to a forced dichotomisation imposed on a continuous spectrum of 
variation within the tissue.  
These results support the representation of the variation in low-grade OA cartilage as a 
continuous spectrum for improved sensitivity (notably, the MOFA results were highly similar 
for analyses based on all patients or knee OA patients only, see below). These results also 
show that the clustering in low-grade cartilage is qualitatively similar when based on knee 
OA patients only, and support the inclusion of samples from hip OA patients in the main 
analysis to increase sample size and boost power for improved robustness of clustering. 
 
MOFA 
First, we did not find any evidence for association between the patient cohorts and any of 
MOFA Factor 1 scores for low-grade OA cartilage, or MOFA Factor 1 or Factor 2 scores for 
synovium (p>0.96 for cohort effect coefficients in all generalised linear models). As an 
example, online supplemental figure 7a shows similar distribution of MOFA low-grade 
Factor 1 scores for patients from all four cohorts.  
Second, we re-ran the low-grade and high-grade OA cartilage analyses based on knee 
osteoarthritis patient samples only (n=77 and n=85, respectively). For each tissue, the 
results were highly similar to the analysis of all patients (gene expression weights for the 
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first MOFA factor and corresponding patient scores showed high correlation: all Pearson 
r>0.99, p<10-15; online supplemental figures 7b-c). 
Finally, we also re-ran the low-grade OA cartilage analysis based on patient samples from 
cohort 4 only (n=50, all knee OA). The results were also highly similar to the analysis of all 87 
patients (gene expression weights for the first MOFA factor and corresponding patient 
scores showed high correlation: Pearson r³0.97, p<10-15; online supplemental figure 7d). 
 
Conclusions and note on cartilage scoring systems 
These results show that the main spectrum of variation in low-grade OA cartilage as 
described in the main results is highly robust and not due to differences between cohorts.  
As detailed in the Methods, multiple normalisation steps were carried out to remove 
technical variation, including application of pSVA and regressing out effects of known 
sample collection and sequencing batches. This could also have removed differences due to 
different cartilage scoring systems used for different cohorts (online supplemental 
methods). As such differences cannot be distinguished from technical variation in the 
current data, future research will be needed to determine which cartilage scoring approach 
is most suited to collect samples that best reflect the inflammatory axis of variation. 
 
 
MOFA sensitivity analyses of female and male patients separately, and 
analysis explicitly adjusting for sex and age  
We carried out sensitivity analyses using MOFA to determine robustness of the results when 
separately analysing low-grade OA cartilage samples from female patients (n=52) and male 
patients (n=35). The results were highly similar to the analysis of all patients: the gene 
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expression weights for the first MOFA factor showed very high correlation (Pearson r=0.99, 
p<10-15; online supplemental figure 8a). Similarly, the patient scores for the first MOFA 
factor in the sensitivity analyses were highly similar to the MOFA low-grade OA Factor 1 
scores in the main analysis (Pearson r=0.99, p<10-15; online supplemental figure 8a). 
Moreover, we applied MOFA to low-grade OA cartilage data after explicitly regressing out 
sex and age effects on expression of each individual gene using generalised linear models. 
Again, the results were highly similar to the main analysis: high correlation of gene weights 
for the first MOFA factors (r=0.99, p<10-15; online supplemental figure 8b) and high 
correlation of patient scores for the first MOFA factors (r=0.92, p<10-15; online supplemental 
figure 8b). 
This provides evidence that the main spectrum of variation in low-grade OA cartilage as 
determined by MOFA is robust and does not merely reflect sex or age effects. 
 
 
PAMR classifier construction based on low-grade cartilage samples from all 
patients  
As a sensitivity analysis for the PAMR classifier, we also carried out classifier construction 
based on low-grade cartilage data from all 87 patients in the discovery set, using the same 
approach as in the main analysis. The resulting classifier contained the same seven genes, 
and yielded highly similar cluster assignment probabilities for all discovery samples from 
knee OA patients (Pearson correlation r=0.999, p<10-10), and for all validation samples 
(Pearson correlation r=0.998, p<10-10). 
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Supplemental methods 
Patients  
Cohorts 1, 2, 4 (knee osteoarthritis) 
This work was approved by Oxford NHS REC C (10/H0606/20 and 15/SC/0132), and samples 
were collected under Human Tissue Authority license 12182, Sheffield Musculoskeletal 
Biobank, University of Sheffield, UK.  
We confirmed that each patient had a joint replacement for osteoarthritis, with no history 
of significant knee surgery (apart from meniscectomy), knee fracture, or knee infection, and 
no malignancy within the previous 5 years. We further confirmed that each patient had not 
used glucocorticoids (systemic or intra-articular) within the previous 6 months, nor any 
other drug associated with immune modulation.  
Cartilage samples from patients in cohort 1 were scored using the OARSI cartilage 
classification system.[8, 9] From each patient, we collected one sample with high OARSI 
grade demonstrating high-grade degeneration (“high-grade OA sample”), and one cartilage 
sample with low OARSI grade demonstrating low-grade degeneration or healthy tissue 
(“low-grade OA sample”). 
Cartilage samples from patients in cohorts 2 and 4 were scored macroscopically using the 
International Cartilage Repair Society (ICRS) scoring system.[10] From each patient, we 
collected one sample with ICRS grade 3 or 4 demonstrating high-grade degeneration (“high-
grade OA sample”), and one cartilage sample of ICRS grade 0 or 1 signifying healthy tissue or 
low-grade degeneration (“low-grade OA sample”). From patients in cohorts 2 and 4, we also 
collected synovial membrane from the suprapatellar region of the knee joint. 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2020-219760–5.:10 2021;Ann Rheum Dis, et al. Steinberg J
For patients in cohorts 1,2, and 4, we obtained information on clinical characteristics (age, 
height, weight, body mass index (BMI), American Society of Anaesthesiologists (ASA) grade 
[11]) from the electronic patient records.  
For each patient, a list of drugs prescribed on the date of sample collection was also 
compiled from the electronic patient record and cross referenced with the patient medical 
history. Prescribed drugs were grouped by pharmacological mechanism into 58 categories 
by two clinical experts (AF & JMW; online supplemental table 4). 
 
Cohort 3 (hip osteoarthritis) 
Samples were collected under National Research Ethics approval reference 11/EE/0011, 
Cambridge Biomedical Research Centre Human Research Tissue Bank, Cambridge University 
Hospitals, UK.  
We confirmed osteoarthritis disease status by examination of the excised femoral head. 
From each patient, we collected a cartilage sample showing a fibrillated or fissured surface 
signifying high-grade degeneration (“high-grade OA sample”), one cartilage sample showing 
a smooth shiny appearance signifying healthy tissue or low-grade degeneration (“low-grade 
OA sample”). 
 
Isolation of chondrocytes  
Cohorts 1,2,4 
Isolation of chondrocytes for patient cohorts 1 and 2 has been described previously,[12] and 
we followed the same protocol to isolate chondrocytes for patients in cohort 4. Briefly, 
osteochondral samples were transported in Dulbecco's modified Eagle's medium 
(DMEM)/F-12 (1:1) (Life Technologies) supplemented with 2mM glutamine (Life 
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Technologies), 100 U/ml penicillin, 100 μg/ml streptomycin (Life Technologies), 2.5 μg/ml 
amphotericin B (Sigma-Aldrich) and 50 μg/ml ascorbic acid (Sigma-Aldrich) (serum free 
media). We then took forward half of each sample for chondrocyte extraction. We removed 
cartilage from the bone, then dissected and washed twice in 1xPBS. The tissue was digested 
in 3 mg/ml collagenase type I (Sigma-Aldrich) in serum free media overnight at 37°C on a 
flatbed shaker. We passed the resulting cell suspension through a 70 μm cell strainer (Fisher 
Scientific), then centrifuged at 400g for 10 minutes. We then washed the cell pellet twice in 
serum free media and centrifuged at 400g for 10 minutes. Subsequently, we resuspended 
the resulting cell pellet in serum free media, counted cells using a haemocytometer, and 
checked viability using trypan blue exclusion (Invitrogen). The optimal cell number for spin 
column extraction from cells was between 4x106 and 1x107. Finally, we pelleted and 
homogenised cells. 
Cohort 3 
The extraction of chondrocytes in the majority of these samples has previously been 
described,[13] with the remaining samples following the same protocol, which was based on 
the protocol for cohorts 1,2, and 4. Briefly, we minced each cartilage portion with a scalpel 
and placed in 20ml of Dulbecco’s modified Eagle medium (Invitrogen) containing 10% foetal 
bovine serum (Invitrogen) and 6 mgml-1 collagenase A (Sigma). We incubated the tissue 
culture flasks overnight to digest the cartilage pieces. We passed the resulting cell 
suspension through a 30 μm filter (Miltenyi) and centrifuged at 400g for 10 minutes. We 
then re-suspended the cell pellet in 1ml of PBS, counted cells using a haemocytometer 
mixed with trypan blue to determine cell viability. 
 
Isolation of synoviocytes  
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We followed a previously established protocol to process synovial samples.[14] Briefly, 
synovial samples were transported in serum free media, as described above. We then 
dissected the synovial membrane from underlying tissue and trypsinised for 1 hour. This 
was followed by tissue digestion in 1mg/ml Collagenase Blend H (Sigma Aldrich) in serum 
free media overnight at 37°C on a flatbed shaker. We passed the resulting cell suspension 
through a 100 μm cell strainer (Fisher Scientific) and centrifuged at 400g for 10 minutes. We 
then washed the cell pellet twice in serum free media, centrifuged at 400g for 10 minutes, 
and re-suspended the resulting cell pellet in serum free media. We counted cells using a 
haemocytometer and checked the viability using trypan blue exclusion (Invitrogen). The 
optimal cell number for spin column extraction from cells was between 4x106 and 1x107. 
Finally, we pelleted and homogenised cells. 
 
RNA extraction  
We used the Qiagen AllPrep RNA Mini Kit to extract RNA and followed manufacturer’s 
instructions, with small variations for cohort 3 as previously described.[13] We froze 
samples at -80°C (cohorts 1, 2, 4) or -70°C (cohort 3) prior to assays. 
 
RNA sequencing  
As preparation for RNA sequencing, poly-A tailed RNA (mRNA) was purified from total RNA 
using Illumina's TruSeq RNA Sample Prep v2 kits. The mRNA was then fragmented using 
metal ion-catalyzed hydrolysis and a random-primed cDNA library was synthesised. We used 
the resulting double-strand cDNA as the input to a standard Illumina library prep, repairing 
ends to produce blunt ends by a combination of fill-in reactions and exonuclease activity. 
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This was followed by A-tailing to allow pooling of samples, adding an “A” base to the blunt 
ends and ligation to Illumina Paired-end Sequencing adapters containing unique index 
sequences. We used KAPA Hifi Polymerase for 10-cycle PCR amplification of libraries. We 
used a post-PCR Agilent Bioanalyzer to quantify samples, then carried out sample pooling 
and size-selection of pools using the LabChip XT Caliper. The multiplexed libraries were 
sequenced on the Illumina HiSeq 2000 for cohort 1 and HiSeq 4000 for cohorts 2-4 (75bp 
paired-ends). Sequenced data underwent initial analysis and quality control on reads as 
standard. The sequencing depth was similar across samples, with 90% of samples passing 
final quality control (see below) having 87.2-129.2 million reads. 
 
We used samtools v1.3.1 [15] and biobambam v0.0.191 [16] to convert cram to fasq files 
after exclusion of reads that failed QC. We then used FastQC v0.11.5 to check sample quality 
[17] and excluded 9 samples accordingly (online supplemental table 5).  
We used salmon 0.8.2 [18] to obtain transcript-level expression estimates, with --gcBias and 
--seqBias flags to account for potential biases, and supplying the GRCh38 cDNA assembly 
release 87 [downloaded from Ensembl: http://ftp.ensembl.org/pub/release-
87/fasta/homo_sapiens/cdna/]. The transcript-level estimates were converted to gene-level 
scaled transcripts per million (TPM) estimates using tximport.[19] This yielded expression 
estimates for 39,037 genes based on Ensembl gene IDs.  
We excluded 4 samples due to low mapping rate (<80%), 3 samples due to non-European 
ancestry recorded in the clinic, 18 samples due to low RIN (<5), 2 samples as duplicates, 8 
samples due to abnormal gene read density plots (detected separately in cartilage and 
synovium for 3 cartilage and 5 synovium samples; all exclusions are listed in online 
supplemental table 5). 
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The resulting final gene expression dataset included 259 samples from 106 patients, with at 
most one sample per patient per tissue (table 1). For cartilage, we retained 15,249 genes 
that showed counts per million (CPM) of ³1 in ³40 samples. For synovium, we retained 
16,004 genes that showed CPM ³1 in ³20 samples.  
 
Sample clustering  
We normalised RNA data from each tissue separately, using limma-voom [20] to remove 
heteroscedasticity from scaled TPM values. Especially when considering clustering within a 
particular tissue, technical effects can influence the results. Consequently, for RNA data, we 
applied pSVA [21] (designed specifically to preserve biological heterogeneity for clustering) 
to the voom-normalised data, separately within low-grade OA cartilage, high-grade OA 
cartilage, and synovium, using the RNA sequencing batches to remove technical variation 
(post-QC, 9 batches for low-grade OA cartilage, 10 batches for high-grade OA cartilage, 8 
batches for synovium). After this step, we obtained residuals from linear regression of the 
post-pSVA-data on an artificial variable indicating RNA sequencing batches and RNA 
extraction batches (RNA extraction from paired samples always in the same batch; in total, 
12 batches for low-grade OA cartilage, 13 for high-grade OA cartilage, 11 for synovium).  
 
For each tissue, we applied ConsensusClusterPlus,[22] a consensus clustering method that 
splits samples into a discrete number of groups, so that samples within a group are more 
similar to each other than to samples outside the group. We used standard settings, with 
scaled gene expression or protein abundance values, a Euclidean distance between samples, 
and a hierarchical clustering algorithm (options innerLinkage="average", 
finalLinkage="average", corUse="complete.obs", clusterAlg="hc"). The maximum number of 
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clusters was 10, with 1000-fold re-sampling for 80% of samples and a fixed seed for 
reproducibility (options maxK=10, reps=1000, pItem=0.8, pFeature=1, 
seed=1262118388.71279). The final number of clusters was chosen based on the Consensus 
Cumulative Distribution Function plots, the Delta Area Plot, and a visual investigation of the 
Consensus Matrices, as advised in the manual. Results were confirmed via additional 
analysis using a distance metric based on Pearson correlation. 
To further verify the results, we also carried out a sensitivity analysis of low-grade and high-
grade OA cartilage clustering by restricting the analysis to samples from knee OA patients 
only (see below). 
 
Differential gene expression between tissue clusters 
To follow up the clustering results for low-grade OA cartilage and synovium, we tested gene 
differential expression between sets of samples based on cluster assignment (applying 
limma to the normalised expression values underlying the clustering, i.e. gene expression 
after voom, pSVA, and regression of batch covariates). The differential expression analysis 
was followed up by gene set enrichment analyses using SPIA and GOseq, with 8 gene 
differential expression FDR thresholds to assess robustness of the association (5%, 0.5%, 
5x10-3, …, 5x10-7). In each analysis, gene set association was defined at the 5% FDR 
threshold. As before for GOseq, genes with positive and negative log-fold-difference 
between clusters were analysed separately. 
 
Associations between tissue clusters and clinical characteristics 
We tested for association between low-grade OA cartilage dichotomous cluster assignment 
(high-inflammation cartilage-Cluster1 versus low-inflammation cartilage-Cluster2) and 
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clinical characteristics using a generalised linear model (via the glm function in R with option 
family=”binomial”). We restricted the analysis to 9 drug categories, each with at least 20 
patients who were also assigned a low-grade OA cartilage or synovium cluster (online 
supplemental table 2).  
To identify the number of effective tests across clinical characteristics (age, height, weight, 
BMI, ASA grade, number of drugs taken) and the 9 drug categories, we calculated pairwise 
correlations across patients using pairwise complete observations. We then obtained and 
eigenvalues of the correlation matrix, and calculated the effective number of tests Neff for 
clinical characteristics as 	
𝑁#$$ = 𝑁 −' 𝐼(𝜆 > 1) ∗ (𝜆 − 1)/  
 
where N=16 is the number of characteristics tested, and l denotes the eigenvalues. Across 
the Pearson and Spearman correlation matrices, we obtained Neff<10.54. We thus used a 
Bonferroni-corrected threshold of p<0.05/10.54=0.0047 to define significance.  
 
As a sensitivity analysis, we tested for association of low-grade OA cartilage dichotomous 
cluster assignment (high-inflammation cartilage-Cluster1 versus low-inflammation cartilage-
Cluster2) using a generalised linear model (via the glm function in R with option 
family=”binomial”), adjusting for i) sex; ii) sex and age; iii) sex, age, and osteoarthritis joint; 
iv) sex, age, and BMI (based on knee osteoarthritis patients only, as we did not have BMI 
information for hip osteoarthritis patients). We also tested associations adjusting for sex 
and age, using the same approach as above but based on data from knee osteoarthritis 
patients only. 
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For association with synovium cluster assignment, we carried out analogous tests for the 




Multi-Omics Factor Analysis (MOFA) and correspondence to sample 
clustering 
To test for patient heterogeneity using a method that can detect both discrete clustering 
and a continuous spectrum of variation, we used Multi-Omics Factor Analysis (MOFA).[3] 
MOFA can integrate data across tissues to discover hidden factors that represent drivers of 
variability between samples or patients. MOFA was run i) jointly on all RNA data; ii) on RNA 
data within each tissue. MOFA identifies a factor score for each sample or patient, 
calculates the variance explained by each factor in each tissue, calculates weights of genes 
on each factor from each tissue, carries out a gene set enrichment for each factor in each 
tissue based on gene weights. All analyses were restricted to genes with unique 
correspondence between Ensembl gene ID and gene name as above. The technical 
parameters applied were gaussian likelihoods, 5000 iterations, a maximum of 100 factors, 
and dropping factors that explain less than 5% during training, with fixed seed 20180613 for 
reproducibility. 
 
We further investigated the correspondence between the discrete clusters identified by 
ConsensusClusterPlus and the spectrum of variation identified by the MOFA as follows. 
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We tested the gene expression differences between subsets of the discrete low-grade OA 
tissue clusters at a MOFA low-grade factor 1 threshold of 0, which corresponded most 
closely to the cluster assignment, with consistent assignment for 84% of patients in the first 
cluster (38 of 45 with score >0) and 83% of patients in the second cluster (35 out of 42 with 
score <0). We analysed gene expression differences between the 38 and 7 samples in 
cartilage-Cluster1 with MOFA Factor 1 values above and below 0, respectively. Analogously, 
we analysed gene expression differences between the 7 and 35 samples in cartilage-
Cluster2 with MOFA Factor 1 values above and below 0, respectively. We applied limma to 
the normalised gene expression values underlying the clustering, i.e. gene expression after 
voom, pSVA, and regression of batch covariates.  
Second, we calculated the Pearson correlation between gene weights from the RNA data on 
the MOFA Factor 1 and the log-fold differences between the two low-grade OA cartilage 
clusters using the cor.test function in R. 
For synovium, we carried out a Pearson correlation analysis between the gene weights on 
the MOFA synovium Factors 1 and 2, and the log-fold differences between synovium-
Cluster1 and synovium-Cluster2, as well as between the synovium subclusters synovium-
Cluster1a and synovium-Cluster1b, and separately, synovium-Cluster2a and synovium-
Cluster2b. 
 
We also checked that the main axes of variation identified by MOFA were not associated 
with technical differences between patient cohorts as follows. We used generalised linear 
models to test for association between the four patient cohorts and each of MOFA Factor 1 
scores for low-grade OA cartilage, and MOFA Factor 1 and Factor 2 scores for synovium.  
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Moreover, we re-ran the low-grade OA cartilage analysis based on patient samples from 
cohort 4 only (n=50), using the same settings for MOFA as in the main analysis. We then 
calculated the Pearson correlation between gene weights for the first MOFA factor with the 
results based on the analysis of all patients. 
Finally, we re-ran the low-grade OA cartilage analysis i) separately based on samples for 
female (n=52) and male (n=35) patients; and ii) for all patients, after explicitly regressing out 
sex and age effects for each gene (using a linear model in R). Again, we used the same 
settings for MOFA as in the main analysis throughout. We calculated the Pearson 
correlation between gene weights for the first MOFA factor with the results of the main 
analysis, and the Pearson correlation between patient scores for the first MOFA factor with 
the results of the main analysis. 
 
Construction of classifier to recapitulate heterogeneity within knee low-
grade OA cartilage 
First, we computed silhouette scores for each low-grade OA sample based on the clustering, 
to calculate how similar each sample is to samples in the same cluster versus the other 
cluster. As the clustering was based on all patients, we included all patients in the 
calculation of silhouette scores, but then restricted the construction of the classifier to knee 
OA patients only. 
To calculate silhouette scores, for each sample 𝑖 in cartilage-Cluster1, we obtained the 
average dis-similarity to other samples in cartilage-Cluster1 (written 𝑗 ∈ 𝐶4, 𝑗 ≠ 𝑖) as 𝑎(𝑖) =
4
|9:|;4 (∑ 1 − 𝑠𝑖𝑚(𝑖, 𝑗)?∈9:,?@A ) where 𝑠𝑖𝑚(𝑖, 𝑗) is the similarity between samples 𝑖 and 𝑗 in 
cartilage-Cluster1 computed by ConsensusCluster, and |𝐶4| is the number of samples in 
cartilage-Cluster1. We then obtained the average dis-similarity of sample 𝑖 to samples in 
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cartilage-Cluster2 as 𝑏(𝑖) = 4|9C| (∑ 1 − 𝑠𝑖𝑚(𝑖, 𝑗)?∈9C ). The silhouette score for sample 𝑖 was 
then calculated as 
D(A);E(A)
FGH	(E(A),D(A). We proceeded analogously for samples in cartilage-Cluster2.  
To train a classifier to recapitulate the low-grade OA cartilage cluster assignment for knee 
OA patients, we considered all samples from these patients with silhouette score >0.2 
(removing 1 sample in low-grade OA cartilage-Cluster1, 2 samples in low-grade OA cartilage-
Cluster2). We also restricted the analysis to 1,027 genes with high expression levels, 
obtained as median scaledTPM value of at least 5,000 across all knee low-grade OA cartilage 
samples. We applied pamr to the 1,027 genes and 74 samples, setting the seed to 20180927 
for all random components. We applied the function pamr.adaptthresh (with options ntries 
= 100, reduction.factor = 0.9) to identify thresholding scales for the classifier training. We 
then used the pamr.train function to train a classifier, and the pamr.cv function to examine 
the classifier error rates in cross-fit validation within the training data. We identified the 
minimum error rate to be reached with a threshold of 5.87, yielding 7 genes and a cross-
validation error rate of 0.08. We then used the pamr.predict function to predict cartilage-
Cluster1 and cartilage-Cluster2 probabilities for all 77 knee low-grade OA samples, with an 
agnostic prior setting of 0.5 for both clusters (options type="posterior",prior=c(0.5,0.5)). 
We then calculated Spearman correlations for the PAMR cluster probabilities and MOFA 
Factor 1 for knee low-grade OA cartilage to verify that the classifier recapitulated the 
continuous spectrum of variation. 
We also carried out a sensitivity analysis by applying the above procedure to construct a 
classifier using samples from all patients in the discovery data.  
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Validation of clustering classifier 
We obtained RNA expression data from low-grade OA cartilage tissue of 60 knee 
osteoarthritis patients undergoing joint replacement (table 1), as described previously.[2] 
This dataset was completely independent of the discovery data, with patient recruitment, 
sample collection and RNA sequencing (Illumina HiSeq 2500) at different sites, transcript 
quantification using a different method (kallisto). We obtained the gene-level expression 
data from Github (file txi.RData on github.com/soulj/OAStratification, accessed 
03/10/2018), with sample batch information provided in a separate file 
(patientDetails_all_withMed.csv). We then carried out further steps to harmonise data 
processing with our approach. First, we used tximport to transform the expression data to 
scaled transcript per million (scaledTPM) levels. We then applied the voom function in the 
limma R package to remove heteroscedasticity, followed by applying pSVA to remove batch 
effects (based on the known batches as listed in patient details). As for the discovery data, 
we calculated residuals from a linear regression of post-pSVA data on batches, and used 
these expression residuals as data post batch effect removal. 
We applied the pamr.predict function to predict cartilage-Cluster1 and cartilage-Cluster2 
probabilities for all 60 samples using the trained 7-gene classifier, with an agnostic prior 
setting of 0.5 for both clusters. We also applied MOFA (with the same parameters and 
options as above) to the data post batch effect removal. Finally, we calculated Spearman 
correlations for the PAMR cluster probabilities and MOFA factor 1.  
The original publication also included a division of samples into 2 groups using non-negative 
matrix factorisation based on known biological networks. The group assignment was also 
provided on Github (file NetNMF_R2_L25.RData). This assignment was compared to a 
cluster assignment based on PAMR 7-gene classifier posterior probabilities. 
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Supplemental figures 
 
Supplemental figure 1. Cluster consensus and tracking plots for the clustering analysis of 
samples within tissues. 
a, Cluster consensus plots for clustering in low-grade OA cartilage, synovium, and high-
grade OA cartilage based on RNA data. The x-axis shows the number k of clusters, 
the y-axis the cluster consensus value (higher values showing stronger clustering). 
For clustering in low-grade OA cartilage and synovium, the cluster consensus value is 
above 0.8 for both clusters when k=2. For high-grade OA cartilage, the cluster 
consensus value is <0.8 for at least one cluster. 
b
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b, High-grade OA cartilage tissue samples from patients do not show a separation into 
two clusters by ConsensusCluster analysis based on RNA data (cluster consensus 
value <0.8). 
c, Cluster tracking plots for low-grade OA cartilage and synovium samples based on 
RNA data. Each column is a sample, coloured by the cluster assignment when 
separating samples into k=2,…,10 clusters (k values in rows). 
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Supplemental figure 2. Gene expression differences between the synovium sub-clusters 
within each cluster are highly correlated. 
The plot shows log-fold-differences of each gene in the comparison of sub-clusters within 
the larger (x-axis) and smaller (y-axis) cluster. Over 99% of the genes with significant 
differences between synovium-Cluster1a and synovium-Cluster1b also had directionally 
concordant differences between synovium-Cluster2b and synovium-Cluster2a, and over 
80% were also significant at 5% FDR, and vice versa (i.e. genes with higher expression in 
synovium-Cluster1a compared to synovium-Cluster1b also had higher expression in 
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Supplemental figure 3. An analysis of synovium samples using Multi-Omics Factor Analysis 
(MOFA) identifies a continuous spectrum of variation between samples, which 
corresponds to the synovium clusters. 
MOFA synovium Factor 1 captures differences between sub-clusters, while synovium factor 
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c, Correlation between MOFA synovium Factor 1 and 2 gene weights for RNA data and 
gene expression differences between synovium clusters and sub-clusters. Inset: 
Pearson correlation, p<10-15. 
C-Cluster: cartilage-Cluster; S-Cluster: synovium cluster 
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Supplemental figure 5. PAMR 7-gene knee low-grade OA cartilage classifier performance. 
PAMR diagnostic plots for a classifier of knee low-grade OA cartilage based on RNA. Left: 
Sample classification error based on the PAMR internal threshold and the corresponding 
number of genes in the classifier. The top panel shows the overall error estimate, the 
bottom panel error rates separately for cartilage-Cluster1 and cartilage-Cluster2. The 
optimal selection as used in the paper included 7 genes and an internal threshold of 5.87 
(vertical line). Right: False Discover Rate (FDR) for between-cluster differences for the genes 
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Supplemental figure 6. Qualitatively similar clustering analyses of low-grade and high-
grade OA cartilage from knee osteoarthritis patients only. 
a, Cluster consensus plots for clustering in low-grade OA cartilage and high-grade OA 
cartilage samples from knee osteoarthritis patients only.  
b, An analysis of knee OA patients only yields the same cluster assignment as the main 
analysis for 91% (70/77) patients, of whom 33 remain assigned to low-grade OA 
cartilage cluster 1 and 37 to low-grade OA cartilage cluster 2. The 4 patients re-
assigned from cluster 1 to cluster 2 have intermediate MOFA low-grade Factor 1 
scores both in the analysis of all patients (left) and the analysis of knee OA patients 
only (right), indicating the re-assignment may be due to forced dichotomisation of a 
a
Cluster consensus plots – knee OA patients only
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continuous spectrum of variation that is highly robust (see also online supplemental 
figures 7-8). p-values shown are from a Mann-Whitney U test. 
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Supplemental figure 7. MOFA sensitivity analyses based on data from knee osteoarthritis 
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a, MOFA low-grade OA cartilage Factor 1 scores do not show differences between 
patient cohorts (confirmed by a formal test using generalised linear models: p>0.96 
for cohort effect coefficients). 
b, A MOFA sensitivity analysis of low-grade OA cartilage samples from knee 
osteoarthritis patients only (n=77) yields result highly similar to the main analysis of 
all patient samples (n=87). Inset: Pearson correlation of gene weights or factor 
scores for MOFA low-grade OA cartilage Factor 1 as determined from the main 
analysis and this sensitivity analysis, p<10-10. 
c, A MOFA sensitivity analysis of high-grade OA cartilage samples from knee 
osteoarthritis patients only (n=85) yields result highly similar to the main analysis of 
all patient samples (n=95). Inset: Pearson correlation of gene weights or factor 
scores for MOFA high-grade OA cartilage Factor 1 as determined from the main 
analysis and this sensitivity analysis, p<10-10. 
d, A MOFA sensitivity analysis of low-grade OA cartilage samples from cohort 4 only 
(n=50) yields result highly similar to the main analysis of all patient samples (n=87). 
Inset: Pearson correlation of gene weights or factor scores for MOFA low-grade OA 
cartilage Factor 1 as determined from the main analysis and this sensitivity analysis, 
p<10-10. 
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Supplemental figure 8. MOFA sensitivity analyses based on data from female and male 
patients separately, or based on regressing out sex and age effects, show robustness of 
results. 
a, MOFA sensitivity analyses of low-grade OA cartilage samples from female 
patients only (n=52, left), male patients only (n=35, middle), or all patients with 
explicitly regressing out sex- and age-effects before MOFA (right): in all three, 
gene expression weights for the first MOFA factor are highly similar to the main 
analysis. Inset: Pearson correlation of gene weights for MOFA low-grade OA 
cartilage Factor 1 as determined from main and sensitivity analyses, p<10-10. 
b, For the same sensitivity analyses as in b, MOFA low-grade OA cartilage Factor 1 
scores for patients are highly similar to the main analysis (left: separate analysis 
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age effects before applying MOFA). Inset: Pearson correlation of MOFA low-
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Supplemental tables 
 
Supplemental table 1. Pathways associated with gene expression differences between 
low-grade OA cartilage clusters or between synovium clusters. 
 
Supplemental table 2. Full association results between patient clinical characteristics and 
low-grade OA sample cluster assignment or synovium cluster assignment, including 
individual drugs assigned to drug classes. 
The nine drug classes which were tested for association are shown (see Methods); for 
complete list of all drugs and assigned drug classes, see online supplemental table 4. 
 
Supplemental table 3. Expression differences between low-grade OA cartilage clusters for 
genes highlighted in previous cartilage clustering analyses. 
 
Supplemental table 4. Assignment of individual drugs to categories by pharmacological 
mechanism. 
 
Supplemental table 5. List of all assayed patient tissue samples with detailed information 
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Data available online 
The RNA sequencing data reported in this paper have been deposited to the EGA 
(https://www.ebi.ac.uk/ega/; accession numbers EGAS00001002255, EGAD00001003355, 
EGAD00001003354, EGAD00001001331). 
 
Data uploaded to https://hmgubox.helmholtz-muenchen.de/d/f5be29c5123244359f73/ 
 
MOFA analysis results 
1. MOFA results: variance captured by each factor in each analysis. Fields highlighted 
where a factor captures at least 20% of the variance for a given tissue. 
2. MOFA results: pathway associations of factors based on MOFA gene-set 
enrichment analysis using Reactome. The enrichment false discovery rate (FDR) is 
shown for each factor and tissue where that factor captures at least 20% of the 
variance. 
3. MOFA gene weights for factor 1 in the low-grade OA cartilage analysis, and factors 
1 and 2 in the synovium analysis. Legend see separate file. 
 
PAMR analysis of patient stratification 
4. For each patient, assignment of low-grade OA and synovium tissue samples to 
clusters, silhouette score for low-grade OA cluster assignment, PAMR posterior 
probability for low-grade OA clusters, and MOFA factor scores. 
5. Construction of low-grade OA cartilage PAMR classifiers and application to 
replication data: R code. This file includes code for applying the classifier to any 
suitable low-grade OA cartilage gene expression data set (presuming scaled TPM 
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gene expression data, for which normalisation and batch effect removal have 
already been carried out). 
6. Construction of low-grade OA cartilage PAMR classifiers and application to 
replication data: R data file. 
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